---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-282578"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:51:02.292895+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Akebia gets 180-day extension to May 2023 to regain Nasdaq bid price compliance; transfer to Capital Market

## Summary
- Received 180-day extension from Nasdaq to regain $1.00 bid price compliance until May 8, 2023.
- Failed to meet initial compliance deadline of November 8, 2022.
- Transfer from Nasdaq Global Market to Nasdaq Capital Market approved, effective November 11, 2022.
- Stock continues trading under symbol AKBA; if not compliant by May 8, 2023, delisting process may begin.
- Company indicated intention to cure deficiency via reverse stock split if necessary.

## SEC filing metadata
- accession: 0001193125-22-282578
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000119312522282578/0001193125-22-282578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000119312522282578/d744480d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-282578
- JSON: https://secwatch.observer/filing/0001193125-22-282578.json
- Plain text: https://secwatch.observer/filing/0001193125-22-282578.txt

## Key facts
- Listing & Compliance Notices
  Akebia Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it complies with the Bid Price Requirement, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company does not regain compliance with the Bid Price Requirement by the Extended Compliance Date, the Staff will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal the Staff’s delisting determination to a Na
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312522282578/0001193125-22-282578-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.